Updated

A large study found that the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can fade quickly once patients stop taking them. Two years after discontinuation, patients faced a 22% higher risk of heart attack, stroke, and death compared with those who continued treatment.